share_log

Goldman Sachs Maintains Sell on PTC Therapeutics, Raises Price Target to $32

Benzinga ·  May 28 11:46

Goldman Sachs analyst Paul Choi maintains PTC Therapeutics (NASDAQ:PTCT) with a Sell and raises the price target from $18 to $32.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment